Page last updated: 2024-11-12

alx-0600

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ALX-0600: glucagon-like peptide 2 (GLP-2) analog [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

teduglutide : A 33-membered polypeptide consisting of His, Gly, Asp, Gly, Ser, Phe, Ser, Asp, Glu, Met, Asn, Thr, Ile, Leu, Asp, Asn, Leu, Ala, Ala, Arg, Asp, Phe, Ile, Asn, Trp, Leu, Ile, Gln, Thr, Lys, Ile, Thr and Asp residues joined in sequence. A glucagon-like peptide-2 receptor agonist used for the treatment of short-bowel syndrome. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16139605
SCHEMBL ID20898050
MeSH IDM0403652

Synonyms (31)

Synonym
197922-42-2
[2-glycine]glucagon-like peptide ii (human)
alx-0600
gattex
[gly2]glp-2
teduglutide
gly(2)-glp-2
7m19191ikg ,
unii-7m19191ikg
alx 0600
hsdb 8337
(gly2)glp-2
glucagon-like peptide ii (2-glycine) (human)
teduglutide [usan:inn:ban]
his-gly-asp-gly-ser-phe-ser-asp-glu-met-asn-thr-ile-leu-asp-asn-leu-ala-ala-arg-asp-phe-ile-asn-trp-leu-ile-gln-thr-lys-ile-thr-asp
hgdgsfsdemntildnlaardfinwliqtkitd
S9935
revestive
glp2-2g
gtpl7049
287714-30-1
alx 0600 (2-glycine-1-33-glucagon-like peptide ii (human))
2-glycine-1-33-glucagon-like peptide ii (human)
SCHEMBL20898050
teduglutide-d8 (phe-d8)
XHA92242
teduglutida
teduglutidum
glucagon-like peptide ii (2-glycine)
teduglutide (mart.)
a16ax08

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Teduglutide treatments were safe and well tolerated."( Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.
Beliveau, M; Caminis, J; Cyran, J; Kesavan, J; Marier, JF; Mouksassi, MS; Shaw, P; Wallens, J; Wells, D; Zahir, H, 2008
)
0.35
"The most common adverse events reported included headache (35%), nausea (31%), and abdominal pain (25%); 7 patients withdrew because of adverse events (gastrointestinal disorders in 4)."( Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
Allard, JP; Gilroy, R; Jeppesen, PB; Messing, B; O'Keefe, SJ; Pertkiewicz, M, 2013
)
0.39
" Outcomes of interest were changes in parenteral nutrient or fluid requirements and adverse event incidence."( Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
Naberhuis, JK; Tappenden, KA, 2016
)
0.43
"Teduglutide reduced PN requirements compared with placebo, whereas adverse event incidence was similar."( Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
Naberhuis, JK; Tappenden, KA, 2016
)
0.43
"Teduglutide appears to be a safe and well-tolerated means to reduce PN dependence in adults, regardless of PN dependence duration."( Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.
Naberhuis, JK; Tappenden, KA, 2016
)
0.43
" Adverse events attributed to teduglutide were obstructive symptoms (n=1), pancreatitis (n=1), asymptomatic lipase and amylase elevation (n=1), nausea (n=1), and abdominal pain (n=1)."( Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
Farraye, FA; Herfarth, H; Kochar, B; Long, MD; Shelton, E; Yajnik, V; Young, L, 2017
)
0.46
" Teduglutide seemed to be safe and the majority of patients were weaned off parenteral support."( Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
Farraye, FA; Herfarth, H; Kochar, B; Long, MD; Shelton, E; Yajnik, V; Young, L, 2017
)
0.46
" All patients reported ≥1 treatment-emergent adverse event (TEAE); 3 patients had TEAEs that were reported as treatment related."( Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
Boullata, JI; Fujioka, K; Iyer, K; Lee, HM; Seidner, DL; Ziegler, TR, 2018
)
0.48
" The available data, albeit limited due to the small number of patients in the so-far performed studies, suggest that teduglutide appears to be safe to use in patients with intestinal failure who are dependent on parenteral support."( Teduglutide for the treatment of short bowel syndrome - a safety evaluation.
Herfarth, HH; Kochar, B, 2018
)
0.48
" Safety end points included treatment-emergent adverse events (TEAEs) and growth parameters."( Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
Carter, BA; Grimm, AA; Hill, S; Horslen, S; Hu, S; Kaufman, SS; Kocoshis, SA; Mercer, DF; Merritt, RJ; Pakarinen, MP; Protheroe, S; Venick, RS; Wales, PW, 2020
)
0.56
" Adverse events (AEs) were reported in all patients; the most common were vomiting (51."( Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
Carter, BA; Cohran, V; Grimm, AA; Hill, S; Horslen, S; Kaufman, SS; Kocoshis, SA; Mercer, DF; Merritt, RJ; Pakarinen, MP; Protheroe, S; Smith, SE; Thompson, JF; Vanderpool, CPB; Venick, RS; Wales, PW; Yoon, M, 2021
)
0.62
" Pharmacovigilance and global data sharing are crucial to support safe prescribing in SBS."( The safety of available treatment options for short bowel syndrome and unmet needs.
Pironi, L; Raschi, E; Sasdelli, AS, 2021
)
0.62
" The adverse events were consistent with the underlying disease and known adverse drug reactions."( Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.
Chen, ST; Grimm, A; Ikeuchi, H; Mizushima, T; Nakamura, S; Ohge, H; Sugita, A; Suzuki, RK; Tazuke, Y; Udagawa, E; Wada, M; Yoon, M, 2023
)
0.91
" All adverse events (AEs) were in line with known impacts of SBS-IF and adverse reactions to teduglutide."( Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chen, ST; Chiba, M; Fagbemi, A; Hill, S; Kaji, T; Masumoto, K; Matsuura, T; Morii, M; Pakarinen, MP; Protheroe, S; Sakui, S; Udagawa, E; Urs, A; Wada, M, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination half-life (t((1/2))) of teduglutide was also influenced by the body weight of participants."( Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.
Beliveau, M; Cyran, J; Gosselin, NH; Marier, JF; Mouksassi, MS; Wallens, J, 2010
)
0.36
" Teduglutide plasma concentrations were measured using a validated liquid chromatography method with tandem mass spectrometric detection, and the primary pharmacokinetic variables (AUCinf and Cmax) were calculated."( Pharmacokinetics of teduglutide in subjects with renal impairment.
Berghöfer, P; Diefenbach, J; Halabi, A; Hartmann, M; Herzog, R; Krause, S; Lahu, G; Nave, R; Schaffer, P, 2013
)
0.39
" The AUCinf and Cmax were also slightly higher in subjects with moderate and severe renal impairment."( Pharmacokinetics of teduglutide in subjects with renal impairment.
Berghöfer, P; Diefenbach, J; Halabi, A; Hartmann, M; Herzog, R; Krause, S; Lahu, G; Nave, R; Schaffer, P, 2013
)
0.39
"In our study population, the primary pharmacokinetic parameters of teduglutide increased with increased severity of renal impairment."( Pharmacokinetics of teduglutide in subjects with renal impairment.
Berghöfer, P; Diefenbach, J; Halabi, A; Hartmann, M; Herzog, R; Krause, S; Lahu, G; Nave, R; Schaffer, P, 2013
)
0.39
" The objectives of this work were, firstly, to develop a population pharmacokinetic (popPK) model based on the available PK data of the entire clinical development program and, secondly, to utilize the model for the justification of the proposed dosing regimen."( Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.
Cyran, J; Facius, A; Lahu, G; Nave, R; Plock, N; Roepcke, S, 2014
)
0.4
"A short-acting (GUB09-123) and a half-life extended (GUB09-145) GLP-1/GLP-2 co-agonist were generated using solid-phase peptide synthesis and tested for effects on food intake, body weight, glucose homeostasis, and gut proliferation in lean mice and in diabetic db/db mice."( Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Fosgerau, K; Hansen, G; Jelsing, J; Jeppesen, PB; Mannerstedt, K; Pedersen, PJ; Pedersen, SL; Vrang, N; Wismann, P, 2018
)
0.48
" In contrast to GUB09-123, sub-chronic administration of a half-life extended GUB09-145 to lean mice caused marked dose-dependent effects on body weight while maintaining its potent intestinotrophic effect."( Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Fosgerau, K; Hansen, G; Jelsing, J; Jeppesen, PB; Mannerstedt, K; Pedersen, PJ; Pedersen, SL; Vrang, N; Wismann, P, 2018
)
0.48
" Effects on body weight and gastric emptying are also observed depending on the pharmacokinetic properties of the molecule."( Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Fosgerau, K; Hansen, G; Jelsing, J; Jeppesen, PB; Mannerstedt, K; Pedersen, PJ; Pedersen, SL; Vrang, N; Wismann, P, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" A controlled study with a more robust design is ongoing in order to determine the optimal dosage of teduglutide for SBS patients to achieve the maximal effect and utility of this drug in clinical practice."( Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Buchman, A; Gregory, J; Holst, J; Howard, L; Jeppesen, PB; Mortensen, PB; Sanguinetti, EL; Scolapio, JS; Tappenden, KA; Ziegler, TR, 2005
)
0.7
" Further studies and the completion of Phase III trials are necessary to determine the appropriate dosage and length of treatment for patients with SBS to gain optimal therapeutic benefit from this drug."( Teduglutide for the treatment of short bowel syndrome.
Ferrone, M; Scolapio, JS, 2006
)
0.33
" Future studies to address the appropriate initial and maintenance dosage and optimal duration of treatment are needed."( Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.
de Villiers, WJ; Mardini, HE, 2008
)
0.35
" The population PK model will help to support adequate drug labeling following SC administrations in patients and determine whether an individualized dosage is required."( Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.
Beliveau, M; Cyran, J; Gosselin, NH; Marier, JF; Mouksassi, MS; Wallens, J, 2010
)
0.36
" The goal was to optimize phase I dosing strategies and the likelihood of achieving target exposure and therapeutic effect."( Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.
Cyran, J; Marier, JF; Mouksassi, MS; Vinks, AA, 2009
)
0.35
" The objectives of this work were, firstly, to develop a population pharmacokinetic (popPK) model based on the available PK data of the entire clinical development program and, secondly, to utilize the model for the justification of the proposed dosing regimen."( Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.
Cyran, J; Facius, A; Lahu, G; Nave, R; Plock, N; Roepcke, S, 2014
)
0.4
" Apraglutide showed greater intestinotrophic activity than the other peptides when administered at less-frequent dosing intervals because of its prolonged half-life."( Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Alagarsamy, S; Croston, G; Dimitriadou, V; Hargrove, DM; Hartwig, J; Laporte, R; Lu, M; Posch, AP; Qi, S; Rivière, PJ; Schteingart, CD; Srinivasan, K; Sueiras-Diaz, J; Wiśniewska, H; Wiśniewski, K, 2020
)
0.56
"Although teduglutide was not cost-effective in weaning PN support in children with SBS, starting teduglutide once natural intestinal adaptation is reduced and adjusting its monthly cost to reflect cost by volume as dictated by weight-based dosing rendered the intervention cost-effective relative to standard of care."( Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.
Avitzur, Y; Belza, C; Gattini, D; Kraus, R; Ungar, WJ; Wales, PW, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
glucagon-like peptide-2 receptor agonistAn agonist that binds to and activates glucagon-like peptide-2 (GLP-2) receptors.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
protective agentSynthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
polypeptideA peptide containing ten or more amino acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345929Human GLP-2 receptor (Glucagon receptor family)2015Clinical drug investigation, May, Volume: 35, Issue:5
Teduglutide: a guide to its use in short bowel syndrome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (8.14)29.6817
2010's93 (54.07)24.3611
2020's65 (37.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.34 (24.57)
Research Supply Index5.31 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (14.86%)5.53%
Reviews44 (25.14%)6.00%
Case Studies22 (12.57%)4.05%
Observational2 (1.14%)0.25%
Other81 (46.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]